Camarda Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Camarda Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,597	Closed	-$1.74M	–	120
2025 Q1	$1.74M	Buy	+3,597	New	+$1.68M	0.79%	41
2022 Q3	–	Sell	-10,768	Closed	-$3.03M	–	84
2022 Q2	$3.03M	Buy	10,768 +2,937	+38%	+$786K	3.01%	12
2022 Q1	$2.04M	Buy	+7,831	New	+$1.86M	0.98%	28
2017 Q1	–	Sell	-20	Closed	-$1K	–	253
2016 Q4	$1K	Buy	+20	New	+$1.63K	﹤0.01%	249

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Camarda Financial Advisors's VRTX Position: Q2 2025 in Review

Camarda Financial Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 3,597 shares — an estimated $1.74M sold.

Camarda Financial Advisors first reported a position in VRTX in Q4 2016 and held it in 4 quarters. The position peaked at $3.03M in Q2 2022. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Camarda Financial Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Camarda Financial Advisors sold 3,597 Vertex Pharmaceuticals shares in Q2 2025, an estimated $1.74M.
Camarda Financial Advisors first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 4 quarters.
Camarda Financial Advisors's Vertex Pharmaceuticals position peaked at $3.03M in Q2 2022.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Camarda Financial Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.